You have read all your free articles, to continue reading subscribe to read the rest of this content.
The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license and collaboration agreement with Regeneron includes five distinct programs, three within cancer and two within infectious diAlready a subscriber Login…
Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The US Food and Drug Administration (FDA) grants ODD Already a subscriber Login You…
Lipigon Pharmaceuticals has signed a new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases. Lipigon, which is located at the Umeå Biotech Incubator, specializes in developing medicines for lipid-related disorders, Already a subscriber Login You have read all your free…
Lundbeck has announced that the phase IIa study (AMBLED) of its novel selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson's disease did not meet the primary study endpoint. There was no statistically significant difference in change fromAlready a subscriber Login You have read…
